Brain scans and genes may guide better schizophrenia drug choices

NCT ID NCT06969755

Recruiting now Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study is for people aged 18-35 experiencing their first episode of psychosis. Researchers will use genetic tests and MRI brain scans to see if certain markers can predict which antipsychotic drug (aripiprazole, risperidone, or clozapine) will work best. The goal is to improve symptom relief and reduce side effects like weight gain. Participants will be followed for 12 weeks to compare how well each drug works based on their individual biology.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aripiprazole, risperidone, and clozapine (antipsychotic drugs)
What this could lead to: If successful, this could help doctors choose the right medication for early schizophrenia based on a patient's genetics and brain scans, leading to better symptom control and fewer side effects.
What could go wrong: This is a Phase 4 study with 180 participants, so results may not apply to everyone. The genetic and brain scan markers are still experimental, and the drugs have known risks like weight gain and blood cell problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHENIA DISORDER

Contacts and locations

Locations

Centre for Addiction and Mental Health
RECRUITING

Toronto, Canada
Feinstein Institute for Medical Research
RECRUITING

Glen Oaks, New York, 11004, United States
McLean
RECRUITING

Belmont, Massachusetts, 02478, United States
The University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of California San Diego
RECRUITING

La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.